Skip to content
NUO

NuvOx

NUOX
Pre-IPO

NuvOx Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oxygen therapeutic solutions to treat diseases characterized by hypoxia.

NuvOx has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.

S-1 Filings

Registration statements filed with the SEC ahead of the planned listing

Competitors

Profile

NuvOx Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oxygen therapeutic solutions to treat diseases characterized by hypoxia. Its core technology utilizes a proprietary perfluorocarbon emulsion that facilitates oxygen transfer from red blood cells to tissues, addressing unmet medical needs in oncology, neurology, and respiratory care.

Competitive position

NuvOx is a pioneer in nano-sized oxygen carriers, holding orphan drug designations and advancing multiple Phase IIb trials for high-mortality conditions.

GeographiesUnited States, Canada, United Kingdom, Australia
Customer segmentsHealthcare providers, Government agencies
Business modelR&D-stage biotechnology, Licensing and royalties
SuppliersSpecialty chemical suppliers, Contract manufacturing organizations, Academic research institutions
CustomersSpecialized medical centers, Emergency medical services, Government health systems

Questions, answered.

Who are NuvOx's competitors?
NuvOx's key competitors include Novocure, Oragenics Inc., Inogen Inc, and others. These companies compete in similar markets and product categories.
Who does NuvOx partner with?
NuvOx's notable partners include FluoroMed, L.P., University of Arkansas, University of Glasgow, and others.
Where is NuvOx headquartered?
NuvOx is headquartered in United States of America.